A Phase 2 Clinical Trial: Xanthohumol Metabolism and Signature (XMaS) in Crohn's Disease
Status:
Recruiting
Trial end date:
2022-12-31
Target enrollment:
Participant gender:
Summary
A pilot study to assess the safety and tolerability of an orally administered natural product
derived from hops, called xanthohumol, in humans with Crohn's Disease, in order to identify a
biological signature of xanthohumol exposure, and to characterize the role of xanthohumol
metabolism by intestinal microorganisms in that signature within adults with Crohn's Disease.
Phase:
Phase 2
Details
Lead Sponsor:
National University of Natural Medicine
Collaborators:
Oregon State University Pacific Northwest National Laboratory